79 Search Results

q=Head%20 , %20Neck

Search Again

David Chhieng , MD, MBA, MSHI, MSEM, MA (HON)

Email: dchhieng@uw.edu

Phone: (206) 598-3315

Dr. Chhieng is director of Anatomic Pathology and a UW profession of pathology. He is surgical pathologist, with expertise in cytopathology, especially in performing and interpreting fine needle aspiration biopsy (FNA). Dr. Chhieng is board certified in Anatomic and Clinical Pathology, Cytopathology, and Clinical Informatics.

View Bio

Bruce Clurman , MD, PhD

Email: bclurman@fredhutch.org

Phone: (206) 667-4524

Dr. Clurman's studies the pathways that regulate cell growth and division in order to understand the molecular mechanisms that drive tumorigenesis and to develop new cancer therapies. His research focuses on two general areas: cellular regulation by the ubiquitin-proteasome system, and control of cell division by cyclin-dependent kinases (CDKs).His clinical practice is focused on hematopoietic stem cell transplantation.

View Bio

Jonathan Cooper , PhD

Email: jcooper@fredhutch.org

Phone: (206) 667-4454

Dr. Cooper studies signaling events that control the architecture of the developing brain. Dr. Cooper is an expert in the signaling pathways that allow cells to communicate with each other and affect the behavior of normal and cancer cells. In particular, his group is interested in studying the Src protein family to understand how they regulate normal cell behavior and their transformation to cancer cells. More recent studies from his laboratory have revealed a mechanism that coordinates cell migrations during brain development and uses many of the same genes and proteins that are important in cancer.

View Bio

Tanya Eadie , PhD, CCC-SLP

Email: teadie@u.washington.edu

Phone: (206) 616-2753

Dr. Eadie's areas of interest are: Auditory-perceptual Evaluation of Voice and Communicative Participation in Head and Neck Cancer. Her goals are to develop a clinical evaluative protocol by which clinicians can more effectively and accurately report the degree of vocal impairment using physiologic, acoustic, and auditory-perceptual measures. In addition, she wants to expand upon the current clinical database addressing the degree of impact on daily voice activity and participation as affected by various types of voice disorders, including those affected by head and neck cancer.

View Bio

Keith Eaton , MD, PhD

Email: kdeaton@u.washington.edu

Phone: (206) 288-7485

Dr. Eaton applies expert research knowledge to treating patients with lung cancer. His clinical expertise is in the areas of lung cancer, head and neck cancer, thyroid cancer, and cancer of unknown primary. His research interests include Immunotherapy and Targeted Therapies.

View Bio

Manuel Ferreira , MD, PhD

Email: manuelf3@u.washington.edu

Phone: (206) 744-932

Dr. Ferreira specializes in the multi-modality treatment for tumors of the skull base, brain and spinal cord, including meningiomas; schwannomas; pituitary tumors; craniopharyngiomas; neurofibromatosis; chordomas and chondrosarcomas; Von Hippel-Lindau; hemangioblastomas; sinonasal tumors of the skull base; and cysts. He uses minimally-invasive skull base procedures to treat these conditions. Moreover he conducts research to understand the genetic basis of these tumors and inherited disorders and wants to use the genetic discovery to predict response to therapy (radio-sensitivity or radio-resistance).

View Bio

Denise Galloway , PhD

Email: dgallowa@fredhutch.org

Phone: (206) 667-4500

Dr. Galloway's lab is interested in the mechanisms by which human papillomaviruses (HPVs) contribute to epithelial cancers. Most of their research has focused on the E6 and E7 oncogenes of the HPVs that have a high risk of progression to cervical cancers, such as HPV 16. In addition to mechanistic studies, the Galloway lab has had long-standing collaborations with epidemiologists and clinicians to understand the natural history of genital HPV infections, and the risk factors that cause only a small subset of women infected with high risk HPVs to progress to cancer. More recently, they have begun to study a different group of HPVs, known as the genus beta HPVs. These beta HPVs commonly infect skin, and may play a role in squamous cell skin cancers (SCSC). They have developed new serologic assays to detect antibodies to many HPVs and to human polyomaviruses.

View Bio

Ajay Gopal , MD

Email: agopal@u.washington.edu

Dr. Gopal specializes in the treatment of lymphoma, chronic lymphocytic leukemia and novel low toxicity therapies.His reseach is focused on developing novel targeted therapies for lymphomas with particular emphasis on radioimmunotherapy-based transplant conditioning regimens, low toxicity Proapoptotic agents for indolent lymphomas, and safe curative regimens for older adults with lymphoma.

View Bio

Bernardo Goulart , MD, MS

Email: bgoulart@fredhutch.org

Phone: (206) 667-2778

Dr. Goulart treats patients for lung cancer and head and neck cancers. His research interests include: Head and neck and lung cancer outcomes research; economical evaluations of head and neck and lung cancer therapies; comparative effectiveness research in cancer and cost-effectiveness analyzes of cancer interventions.

View Bio

Philip Greenberg , MD

Email: pgreen@u.washington.edu

Phone: (206) 543-8306

Dr. Greenberg's laboratory is involved in studies elucidating the immunobiology of host T cell responses to infectious viruses and transformed cells. His group used adoptive therapy approach with cloned T cells to both, elucidate the immunobiology of human malignancies and infections and to develop novel immune-based therapies. Clinical trials of adoptive T cell therapy are now underway in patients with leukemia.

View Bio

Barry Gumbiner , PhD

Email: gumbiner@uw.edu

Phone: 206-884-5116

Dr. Gumbiner and his team study how cadherin cell adhesion molecules and associated catenin proteins control tumor development and progression. Cadherins and catenins play important roles in the morphogenesis, maintenance, and regeneration of tissues, and alterations in their functions are important in cancer. One major effort of the laboratory is to understand how cadherins signal into the cell to control growth and differentiation through regulation of both the Wnt-beta-catenin pathway and the Hippo signaling pathway; the latter inhibits cell proliferation and participates in organ size control. Cadherins mediate contact inhibition of growth by stimulating the Hippo pathway, while growth factors, such as EGF, inhibit the Hippo pathway. They are investigating how these modes of regulation of the Hippo pathway affect the development of different types of tumors. Another major effort of the laboratory is to understand how cadherin adhesive function at the cell surface is regulated to control tissue architecture and tumor cell invasion. Loss of E-cadherin expression associated with the epithelial-mesenchymal transition (EMT) is known to promote tumorigenesis and metastasis. However, many tumors and metastases retain E-cadherin expression, and they have found that instead it can be inactivated at the cell surface to cause the loss in function. They have generated a novel class of monoclonal antibodies that activate E-cadherin at the cell surface to restore its adhesive function, and are evaluating whether they reduce tumor invasion and metastasis in animal models. He and his team are also studying how catenins and cancer-associated mutations in E-cadherin affect its ability to switch to the active state and regulate tumor development. The mechanisms by which cadherins and catenins affect tumor growth are varied and complex and offer potential approaches for intervention.

View Bio

Mark Headley , PhD

Email: mheadley@fredhutch.org

Phone: (206) 667-3619

Dr. Headley is working to understand the cellular and molecular dynamics that underlie tumor metastasis (the spread of cancer cells from a primary tumor to distant organs). The main focus of his lab is to understand how tumor-immune cell interactions variably promote or defend against metastasis. For most cancer patients, metastasis is the leading cause of death. Of particular note, metastasis to the lung is one of the most common and most detrimental sites of tumor spread, and Dr. Headley is especially interested in understanding lung metastasis. He has developed a suite of cutting-edge tools to enable these studies. His lab uses advanced microscopy and surgical techniques to directly visualize tumor cells and immune cells in live lungs in real-time, interrogating the unique lung environment during tumor metastasis with unprecedented detail by pairing this unique microscopy approach with high-resolution single cell profiling. Dr. Headley has recently identified a unique process by which burgeoning metastatic cells shed large cytoplasmic particles from the earliest moments of metastasis. These particles, known as cytoplasts or microparticles, form a platform for engaging a particular class of immune cells called myeloid cells. Notably, during the first hours of metastasis, particular myeloid cells with protumoral properties (macrophages) versus anti-tumoral properties (dendritic cells and patrolling monocytes) encounter and ingest the tumor-derived particles. Dr. Headley seeks to understand how this particular facet of immune-tumor engagement defines anti-tumor immune responses and patient outcomes. His findings will be critical to designing new therapies that can debilitate prometastatic myeloid cell functions while enhancing anti-tumor functions, thereby saving more lives.

View Bio

Noah Hoffman , MD, PhD

Email: ngh2@uw.edu

Phone: (206) 598-7932

Dr. Hoffman's clinical interests and responsibilities include the development and application of software and processes for the collection, management, and display of data generated in the clinical laboratory. His research is focused on creating applications and algorithms to classify medically important microorganisms using biological sequence information.

View Bio

Jeffrey Houlton , MD

Email: jhoulton@uw.edu

Phone: (206) 543-5230

Dr. Houlton is a surgical oncologist who specializes in treating patients with head and neck cancers. His research focuses on clinical outcomes research related to microvascular reconstructive surgery, head & neck cancer treatment, and thyroid/parathyroid surgery.

View Bio

Christopher Kemp , PhD

Email: cjkemp@fredhutch.org

Phone: (206) 667-4252

Dr. Kemp is an expert on tumor suppressor genes and their roles in cancer progression and response to therapy. In addition to using mouse models to understand cancer biology, Dr. Kemp has pioneered the use of mouse models for identifying new biomarkers of cancer and for identifying new cancer drug targets using functional genomics. Dr. Kemp plays a leading role in several national research consortia including the NCI's Mouse Models of Human Cancer Consortia and the Cancer Target Discovery and Development Network. Dr. Kemp's research focuses on understanding how environmental exposure to carcinogens interacting with the genetic susceptibility of the host leads to cancer. He studies multistage carcinogenesis in the mouse in order to model the entire natural history of neoplastic development from the initiated cell to clonal evolution to a fully malignant tumor. His work focuses on the role of the p53 signaling pathway in various cancer models.

View Bio

Linda Ko , PhD, MPH

Email: lko@fhcrc.org

Phone: (206) 667-7182

Dr. Ko is the director of the Center for Health Communication Intervention (CHEALCI). She is a behavioral scientist with expertise in the development, testing, and evaluation of health communication strategies. Her work draws from the discipline of communication, marketing, social epidemiology, and social and behavioral sciences. Her research aims to understand community behavior within the socio-cultural context, develop interventions that will address those behaviors and translate knowledge through community-based participatory research.

View Bio

Charles Kooperberg , PhD

Email: clk@fredhutch.org

Phone: (206) 667-7808

Dr. Kooperberg's main research area is nonparametric function estimation and the analysis of high dimensional data, in particular as applied to genomic and proteomics data.

View Bio

George Laramore , PhD, MD

Email: georgel@u.washington.edu

Phone: (206) 598-4110

Dr. Laramore specializes in treating patients for salivary gland tumors, head and neck cancer, sarcoma of the soft tissue and bone, and genitourinary tumors particularly prostate cancer. He is also lead investigator for several clinical trials evaluating radiation therapy in several types of cancers. He also has an interest in the use of boron neutron capture therapy (BNCT) to treat certain types of cancer.

View Bio

Christopher Li , MD, PhD

Email: cili@fredhutch.org

Phone: (206) 667-7444

Dr. Li's research focuses on breast cancer and understanding factors related to its etiology and outcomes using a multidisciplinary approach. He studies the relationships between various hormonal exposures and risks of different types of breast cancer based on their morphology and expression of different tumor markers, risk factors for second primary breast cancer among breast cancer survivors, identifying markers that could be used for the early detection of different cancers using various proteomic platforms, examining disparities in cancer stage, treatment, and survival by race/ethnicity.

View Bio

Jay Liao , MD

Email: jayliao@uw.edu

Phone: (206) 598-4100

Dr. Liao treats patients with head and neck cancers, salivary gland cancers, skin cancers, genitourinary cancers, and prostate cancer. He specializes in the treatment of head and neck cancers with a number of radiation therapy techniques including IMRT, electron therapy, and fast neutron therapy.

View Bio